Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is one of the most promising mid-cap healthcare stocks under $50. On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish sentiment and assigned a Buy rating to Kiniksa Pharmaceuticals International (NASDAQ:KNSA). With a price target of $45, she anticipates the stock to soar by another 15.77% from the … Read more